News Novartis sheds staff as Entresto patent expiry looms Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.
News FDA approves first generics of anticoagulant Xarelto The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.
News BMS extends its cost-cutting drive by another $2bn BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.
News Novartis less exposed to US pricing pressure, says Jimenez Europe and Asia account for a large share of company's income.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face